Article Information
- Received October 3, 2002
- Revision received November 26, 2002
- Accepted January 8, 2003
- First published March 15, 2003.
- Version of record published March 15, 2003.
Author Information
- William E. Klunk1,
- Yanming Wang2,
- Guo-feng Huang2,
- Manik L. Debnath1,
- Daniel P. Holt2,
- Li Shao1,
- Ronald L. Hamilton3,
- Milos D. Ikonomovic4,
- Steven T. DeKosky4, and
- Chester A. Mathis2
- 1Laboratory of Molecular Neuropharmacology, Department of Psychiatry, Western Psychiatric Institute and Clinic,
- 2PET Facility, Department of Radiology,
- 3Division of Neuropathology, Department of Pathology, and
- 4Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213
Author contributions
Disclosures
- Received October 3, 2002.
- Revision received November 26, 2002.
- Accepted January 8, 2003.
This work was supported in part by the Alzheimer's Association (Grants IIRG-95-076 and TLL-01-3381 to W.E.K. and NIRG-00-2335 to Y.W.), the National Institutes of Health (Grants AG01039 and AG20226 to W.E.K., AG18402 to C.A.M., and AG05133 to S.T.D.), and Institute for the Study of Aging/American Federation of Aging Research (Y.W.). We thank Dr. Bryan Roth (Case Western Reserve University) and Dr. Linda Brady [National Institute of Mental Health (NIMH)] for allowing us access to the NIMH Psychoactive Drug Screening Program. We thank Dr. Robert Sweet for his help in procuring the appropriate tissue samples and the families that made brain tissue available to the University of Pittsburgh Alzheimer Disease Research Center Brain Bank.
Correspondence should be addressed to Dr. William E. Klunk, University of Pittsburgh, 705 Parran Hall– GSPH, 130 DeSoto Street, Pittsburgh, PA 15213. E-mail: klunkwe{at}msx.upmc.edu.
